CD4 and non-small cell lung carcinoma: reported that apCAFs directly activated CD4+ effector T cells in NSCLC and promoted the survival of CD4+ effector T cells through the expression of C1Q molecules and proposed an innovative conceptual framework suggesting that efficient MHC class II immunity in NSCLC requires in situ antigen presentation by CD4+ T cells within the TME (17).